Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
To better understand the physiologic excretion and/or catabolism of circulating peripheral amyloid beta (Abeta), we labeled human Abeta40 (monomeric, with predominant unordered structure) and Abeta42 (mixture of monomers and oligomers in approximately 50:50 ratio, rich in beta-sheet conformation) with either Na(125)I or (125)I-tyramine cellobiose, also known as the cell-trapping ligand procedure, testing their blood clearance and organ uptake in B6SJLF1/J mice. Irrespective of the labeling protocol, the peptide conformation, and the degree of oligomerization, both Abeta40 and Abeta42 showed a short half-life of 2.5-3.0 min. The liver was the major organ responsible for plasma clearance, accounting for >60% of the peptide uptake, followed by the kidney. In vivo, hepatocytes captured >90% of the radiolabeled peptides which, after endocytosis, were preferentially catabolized and excreted into the bile. Biliary excretion of intact as well as partially degraded Abeta species became obviously relevant at doses above 10 microg. The use of biotin-labeled Abeta allowed the visualization of the interaction with HepG2 cells in culture, whereas competitive inhibition experiments with unlabeled Abeta demonstrated the specificity of the binding. The capability of the liver to uptake, catabolize, and excrete large doses of Abeta, several orders of magnitude above its physiologic concentration, may explain not only the femtomolar plasma levels of Abeta but the little fluctuation observed with age and disease stages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The rapid degradation of Aβ in the periphery (t1/2 = 2–3 min) precludes a direct and sensitive measurement of the rate of Aβ appearance from brain into blood (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The rapid degradation of Aβ once it enters the blood from brain precludes direct and reliable measurement of its influx rate by conventional means (27, 28).”
From Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) · cites this paper as [27]
In the citing paper
“The liver clears approximately 60% of circulating Aβ.226”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [226]
Citations
Cites
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease
Lue, L.-F., Kuo, Y.-M., Roher, A. E., Brachova, L., Shen, Y., Sue, L., Beach, T., Kurth, J. H., Rydel, R. E., & Rogers, J. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65184-x · Cited by 1,530
Production of the Alzheimer Amyloid β Protein by Normal Proteolytic Processing
Shoji, M., Golde, T. E., Ghiso, J., Cheung, T. T., Estus, S., Shaffer, L. M., Cai, X.-D., McKay, D. M., Tintner, R., Frangione, B., et al. (1992) · Science · doi:10.1126/science.1439760 · Cited by 1,447
Self-citationShibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
Self-citationTargeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?
Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989
Basic and Clinical Pharmacology
Wingard, L. B. (1983) · Anesthesia & Analgesia · doi:10.1213/00000539-198308000-00015 · Cited by 630
Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains
Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618
Research works printed but not linked: 5
- Seglen, 1993, Methods Toxicol., 1, 231
- Friedman, 1993, Methods Toxicol., 1, 292
- Baltz, 1985, Clin. Exp. Immunol., 59, 235
- Authier, 1996, Clin. Investig. Med., 19, 149
- Hone, 2003, J. Alz. Dis., 5, 1
Cited by
Items 101–200 of 209
Initiative, A. D. N., Zhu, X., Wang, H.-F., Jiang, T., Lu, H., Tan, M., Tan, C., Tan, L., Tan, L., & Yu, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9638-8 · Cited by 27
Chandrashekar, D. V., Roules, G. C., Jagadeesan, N., Panchal, U. R., Oyegbesan, A., Imiruaye, O. E., Zhang, H., Garcia, J., Kaur, K., Win, S., et al. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106570 · Cited by 29
“First, hepatic LRP-1 is the major receptor involved in the peripheral clearance of A β (Ghiso et al., 2004), and a reduction in hepatic LRP-1 suppressed peripheral clearance of A β in WT rodents (Tamaki et al., 2006) and increased brain A β load in the APP/PS1 transgenic AD mice treated with…”
Effects of medications on plasma amyloid beta (Aβ) 42: Longitudinal data from the VITA cohort
Blasko, I., Jungwirth, S., Jellinger, K. A., Kemmler, G., Krampla, W. W., Weissgram, S., Wichart, I., Tragl, K. H., Hinterhuber, H., & Fischer, P. A. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.10.010 · Cited by 25
Brain neprilysin activity and susceptibility to transgene-induced Alzheimer amyloidosis
Carter, T. L., Pedrini, S., Ghiso, J. A., Ehrlich, M. E., & Gandy, S. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.09.022 · Cited by 27
Self-citationN-terminally truncated Aβ4-x proteoforms and their relevance for Alzheimer’s pathophysiology
Rostagno, A. A., Cabrera, E., Lashley, T., & Ghiso, J. A. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00303-3 · Cited by 24
“Once cleared to the blood stream, consistent with its very low and steady concentration in plasma, the fulllength Aβ has a very short half-life of ~ 3 min in mice, similar to that of the peptide hormone insulin or oxytocin [53].”
BackgroundSelf-citationSwaminathan, S. K., Zhou, A. L., Ahlschwede, K. M., Curran, G. L., Lowe, V. J., Li, L., & Kandimalla, K. K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.120.265876 · Cited by 25
“The apparent decrease in plasma clearance of [ 125 I]A b 42 in the presence of 4F could be due to altered A b 42 clearance mechanisms in kidneys and liver, which represent the major organs responsible for systemic A b clearance (Ghiso et al., 2004).”
BackgroundDifferential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide
Molina-Fernández, R., Picón-Pagès, P., Barranco-Almohalla, A., Crepin, G., Herrera-Fernández, V., García-Elías, A., Fanlo-Ucar, H., Fernàndez‐Busquets, X., García‐Ojalvo, J., Oliva, B., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac243 · Cited by 23
“11 During ageing, the activity of β secretase increases, favouring A β production, 12 whereas its degradation and clearance from the brain decrease.”
Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer’s Disease
Tsoy, A., Umbayev, B. A., Kassenova, A., Kaupbayeva, B., & Askarova, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010964 · Cited by 27
“It has been shown that, in the bloodstream, A β presented predominantly in bounded forms [50], and the half-life of circulating peripheral A β is approximately 2.5–15 min [51,52], while in AD patients, the level of non-bound A β is increased up to 3–4 times [53].”
BackgroundInfluentialShie, F., Shiao, Y.-J., Yeh, C.-W., Lin, C.-H., Tzeng, T.-T., Hsu, H.-C., Huang, F.-L., Tsay, H.-J., & Liu, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134531 · Cited by 23
Herrero-Labrador, R., Trueba-Sáiz, Á., Martinez‐Rachadell, L., de Sevilla, M. E. F., Zegarra-Valdivia, J. A., Pignatelli, J., Díaz-Pacheco, S., Fernandez, A. M., & Torres‐Alemán, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249675 · Cited by 23
“Of note, hepatocytes, the main source of circulating IGF-I [14], are the major disposal system for circulating Aβ in mice [15], and previous evidence has shown that insulin, a hormone closely related to IGF-I, favors Aβ uptake by hepatocytes [16].”
BackgroundDeglycosylated Anti-Aβ Antibody Dose–Response Effects on Pathology and Memory in APP Transgenic Mice
Karlnoski, R., Rosenthal, A., Alamed, J., Ronan, V., Gordon, M. N., Gottschall, P. E., Grimm, J., Pons, J., & Morgan, D. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-008-9114-6 · Cited by 25
“When free Aβ is injected intravenously into mice, it is cleared within 10 min (Ghiso et al. 2004).”
BackgroundMcInerney, M. P., Short, J. L., & Nicolazzo, J. A. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0077-5 · Cited by 22
Abu‐Elfotuh, K., Ragab, G. M., Salahuddin, A., Jamil, L., & Haleem, E. N. A. A. (2021) · Molecules · doi:10.3390/molecules26216752 · Cited by 25
“The liver is the primary organ that metabolizes more than 60% of Aβ [14].”
BackgroundLiu, L., Gracely, E. J., Yin, X., & Eisen, H. J. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i1.69 · Cited by 17
Kameshima, N., Nanjo, T., Fukuhara, T., Yanagisawa, D., & Tooyama, I. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.02.026 · Cited by 15
Liu, L., Liang, J., Liu, Y.-H., Liu, B., Dong, X., Cai, W.-H., & Zhang, N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30523 · Cited by 17
“LRP1 is widely expressed in various cell types in the brain and periphery, primarily responsible for the rapid uptake and subsequent clearance of peripheral A β [123,124].”
BackgroundRetractedIs abeta a sufficient biomarker for monitoring anti-abeta clinical studies? A critical review
Moreth, J., Mavoungou, C., & Schindowski, K. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00025 · Cited by 15
“Finally, Aβ is rapidly eliminated by hepatic and renal degradation (Ghiso et al., 2004).”
BackgroundAbbasowa, L., & Heegaard, N. H. H. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.050 · Cited by 17
Richman, M., Perelman, A., Gertler, A. A., & Rahimipour, S. (2012) · Biomacromolecules · doi:10.1021/bm301401b · Cited by 15
Darabi, S., Gorgich, E. A. C., Moradi, F., & Rustamzadeh, A. (2025) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2025.01.004 · Cited by 15
A Preliminary Study of Cu Exposure Effects upon Alzheimer’s Amyloid Pathology
Pilozzi, A. R., Yu, Z., Carreras, I., Cormier, K., Hartley, D. M., Rogers, J. T., Dedeoglu, A., & Huang, X. (2020) · Biomolecules · doi:10.3390/biom10030408 · Cited by 14
Maltsev, A. V., Santockyte, R., Bystryak, S. M., & Galzitskaya, O. V. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131562 · Cited by 17
Chen, J., Wang, L., Zhou, Y., Zhao, S., Chen, Q., & Zheng, K. (2026) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2026.100478 · Cited by 15
Huang, L., Liu, M., Li, Z., Li, B., Wang, J., & Zhang, K. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00865 · Cited by 16
Ishima, Y., Mimono, A., Chuang, V. T. G., Fukuda, T., Kusumoto, K., Okuhira, K., Suwa, Y., Watanabe, H., Ishida, T., Morioka, H., et al. (2019) · IUBMB Life · doi:10.1002/iub.2203 · Cited by 13
Plasma amyloid-β, Aβ1-42, load is reduced by haemodialysis
Rubio, I., Caramelo, C. A., Gil, A., López, M. D., & de Yébenes, J. G. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10413 · Cited by 14
Cho, E. B., Seo, S. W., Kim, H., Lee, J., Yoon, U., Im, K., Kim, G. H., Noh, Y., Cho, H., Yoon, C. W., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121180 · Cited by 13
A Translational Systems Pharmacology Model for Aβ Kinetics in Mouse, Monkey, and Human
Karelina, T., Demin, O. O., Nicholas, T., Lu, Y., Duvvuri, S., & Barton, H. A. (2017) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12211 · Cited by 13
Antifibrotic Effects of Amyloid-Beta and Its Loss in Cirrhotic Liver
Buniatian, G. H., Weiskirchen, R., Weiß, T. S., Schwinghammer, U., Fritz, M., Seferyan, T., Proksch, B., Glaser, M., Lourhmati, A., Buadze, M., et al. (2020) · Cells · doi:10.3390/cells9020452 · Cited by 14
“Although the liver generates, takes up, and degrades Aβ peptides [1], little is known about its role in healthy and cirrhotic liver.”
BackgroundSun, H., Gao, X., Niu, J., Chen, P., He, S., Xu, S., & Ge, J. (2024) · eneuro · doi:10.1523/eneuro.0310-24.2024 · Cited by 12
Gao, L., Jiang, Y., Wei, S., Shang, S., Li, P., Chen, C., Dang, L., Wang, J., Huo, K., Deng, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180399 · Cited by 12
Age-Dependent Changes in the Plasma and Brain Pharmacokinetics of Amyloid-β Peptides and Insulin
Zhou, A. L., Sharda, N., Sarma, V., Ahlschwede, K. M., Curran, G. L., Tang, X., Poduslo, J. F., Kalari, K. R., Lowe, V. J., & Kandimalla, K. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-215128 · Cited by 12
“The liver and kidneys are the major organs responsible for clearing A (cid:2) from the periphery [37], but it remains poorly understood how systemic A (cid:2) clearance is affected during normal aging and in AD.”
Reduced estimated glomerular filtration rate in Alzheimer's disease
Kerr, E., Craig, D., McGuinness, B., Dynan, K., Fogarty, D. G., Johnston, J. A., & Passmore, A. P. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2197 · Cited by 13
“Copyright # 2009 John Wiley & Sons, Ltd. Evidence suggests that Ab deposition and plaque formation is a dynamic process involving a fine balance of Ab production and clearance from the brain (Zlokovic et al., 2000; Selkoe 2001; Ghiso et al., 2004; Bates et al., 2008).”
BackgroundAssociations of liver function with plasma biomarkers for Alzheimer’s Disease
Zhang, B., Zhang, C., Wang, Y., Cheng, L., Wang, Y., Qiao, Y., Peng, D., & Initiative, A. D. N. (2024) · Neurological Sciences · doi:10.1007/s10072-023-07284-9 · Cited by 12
Mei, X., Zhu, L., Zhou, Q., Li, X., & Chen, Z. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00116-z · Cited by 13
LRP1 at the crossroads of Aβ clearance and therapeutic targeting in Alzheimer’s disease
Deng, Y., Yin, H., Lu, Z., Lan, H., Liu, W., Zuo, C., Pan, N., Tian, X., & Gong, Q. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1669405 · Cited by 16
Cao, W., Tian, S., Zhang, H., Zhu, W., An, K., Shi, J., Yuan, Y., & Wang, S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00743 · Cited by 10
“In the central nervous system, Aβ is mainly cleared through LRP1 across the BBB. LRP1 is a major receptor for Aβ in the liver, where the majority of plasma Aβ is cleared (Hone et al., 2003; Ghiso et al., 2004; Tamaki et al., 2006).”
BackgroundExplore the role of CR1 genetic variants in late-onset Alzheimer’s disease susceptibility
Lu, L., Yao, Q.-Y., Ruan, S.-S., Hu, J.-W., Long, W.-J., Dai, W.-Z., Ma, T., & Zhu, X.-C. (2021) · Psychiatric Genetics · doi:10.1097/ypg.0000000000000291 · Cited by 13
Consequences of Amyloid‐β Deficiency for the Liver
Buniatian, G. H., Schwinghammer, U., Tremmel, R., Cynis, H., Weiß, T. S., Weiskirchen, R., Lauschke, V. M., Youhanna, S. C., Ramos, I., Valcárcel, M., et al. (2024) · Advanced Science · doi:10.1002/advs.202307734 · Cited by 10
Qin, H., Cui, T., Liu, Z., Zhou, Y., Niu, J., Ren, J., & Qu, X. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c02734 · Cited by 10
Nourbakhsh, F., Read, M. I., Barreto, G. E., & Sahebkar, A. (2020) · IUBMB Life · doi:10.1002/iub.2369 · Cited by 10
“It was revealed that Aβ40 and Aβ42 are the important isoforms of Aβ, which are distinct by the difference at their end Cterminals.(93,94) Aβ42 deposition is considered an early event in the AD process, which aggregates to the neurotoxic Aβ fibrils.”
BackgroundBlood-based biomarkers for Alzheimer’s disease: influence of kidney function
Gaetani, L., Bellomo, G., Nardi, G., Toja, A., Streva, C., Giombetti, E., Torrigiani, E. G., Paoletti, F. P., Villa, A., Tozzi, A., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-01970-4 · Cited by 11
“For plasma NfL, nor plasma Aβ40 nor plasma Aβ42 improved the association with CSF NfL. Aβ40 and Aβ42 share a similar metabolic pathway, systemic catabolism, and are likely filtered by the kidneys in the same way [28].”
Sensory gamma entrainment: Impact on amyloid protein and therapeutic mechanism
Hu, J., Zheng, L., Guan, Z., Zhong, K., Huang, F., Huang, Q., Yang, J., Li, W., & Li, S. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110750 · Cited by 10
“61], as well as certain tissues and organs, including the liver and kidney[62-66].”
Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study
Wiest, R., Weiß, T. S., Danielyan, L., & Buechler, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122669 · Cited by 9
“Labeled Aβ42 peptides were, indeed, taken up by the liver and excreted in bile [11].”
BackgroundDas, R., Nachbar, R. B., Edelstein‐Keshet, L., Saltzman, J. S., Wiener, M. C., Bagchi, A., Bailey, J. A., Coombs, D., Simon, A. J., Hargreaves, R. J., et al. (2010) · Bulletin of Mathematical Biology · doi:10.1007/s11538-010-9540-5 · Cited by 9
Serum amyloid beta 42 levels correlated with metabolic syndrome and its components
Li, K., Zhou, X., Liu, Y., Li, D., Li, Y., Zhang, T., Fu, C., Li, L., Hu, Y., & Jiang, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1278477 · Cited by 12
Peng, H., Bukuroshi, P., Durk, M. R., Grootendorst, P. V., Yan, X., Pan, S. R., de Lannoy, I. A. M., & Pang, K. S. (2021) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2297 · Cited by 9
Wei, S., Dang, L., Gao, F., Wang, J., Wang, J., & Qu, Q. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220240 · Cited by 9
“In addition to the liver, A (cid:2) -sLRP1 complexes and free A (cid:2) can also be eliminated by the kidney [10].”
Dang, L., Wei, S., Zhao, Y. C., Zhou, R., Shang, S., Gao, F., Wang, J., Wang, J., & Qu, Q. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02398-1 · Cited by 8
Fontana, I. C., Ferreira, P. C. L., Miron, D., Santos, L. E., Ferreira, S. T., Souza, D. O., Gosmann, G., Zimmer, E. R., & Zimmer, A. R. (2021) · Journal of Chromatography A · doi:10.1016/j.chroma.2021.462024 · Cited by 9
Maltsev, A. V., & Galzitskaya, O. V. (2010) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20105606624 · Cited by 8
Hatip, F. F. B., & Hatip‐Al‐Khatib, I. (2013) · Life Sciences · doi:10.1016/j.lfs.2012.12.004 · Cited by 8
β-Amyloid peptide (1–40) in the brain reaches the nasal cavity via a non-blood pathway
Kameshima, N., Yanagisawa, D., & Tooyama, I. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.03.016 · Cited by 8
Effect of Kidney Dysfunction on Cerebral Cortical Thinning in Elderly Population
Chen, C., Chen, Y., Chiu, M., Chen, T., Tsai, P., Chen, J., Yen, C., Tang, S., Yeh, S., & Chen, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-02537-y · Cited by 8
Acute Hyperglycemia Induced by Hyperglycemic Clamp Affects Plasma Amyloid-β in Type 2 Diabetes
Rolandsson, O., Tornevi, A., Steneberg, P., Edlund, H., Olsson, T., Andréasson, U., Zetterberg, H., & Blennow, K. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-230628 · Cited by 8
“In contrast, in brain parenchymal tissue, the majority of A (cid:2) s are A (cid:2) 1 – 42 due to its higher propensity for self-aggregation [12].”
Maltsev, A. V., Dovidchenko, N. V., Uteshev, V. K., Sokolik, V. V., Shtang, O. M., Yakushin, M. A., Sokolova, N. M., Surin, A. K., & Galzitskaya, O. V. (2013) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20135902144 · Cited by 7
Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease
Hone, E., Lim, F., & Martins, I. J. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch7 · Cited by 9
Bostick, J. W., Connerly, T. J., Thron, T., Needham, B. D., Fonseca, M. D. C., Kaddurah‐Daouk, R., Knight, R. D., & Mazmanian, S. K. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.07.028 · Cited by 8
“The liver, kidneys, spleen, and small intestine are important sites for the clearance of circulating A β and may act as hubs for activation of systemic immunity (Ghiso et al., 2004; Yu et al., 2022).”
Martins, I. J., Gupta, V. B., Wilson, A. C., Fuller, S. J., & Martins, R. N. (2014) · Current Proteomics · doi:10.2174/157016461103140922163729 · Cited by 11
Peng, H., Noh, K., Pan, S. R., Saldivia, V., Serson, S., Toscan, A., de Lannoy, I. A. M., & Pang, K. S. (2020) · Drug Metabolism and Disposition · doi:10.1124/dmd.120.090886 · Cited by 9
Bhattacharjee, A., & Roy, P. K. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2154842 · Cited by 8
“Our aforesaid proposition is illustrated in Figure 1, which we have constructed using data from Ghiso et al. (2004).”
MethodShaw, S., Porel, P., & Aran, K. R. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10485-4 · Cited by 6
“The inhibition of Aβ40 aggregation by human CSF indicates that specific molecules may capture soluble Aβ (sAβ) that circulates in the fluid, the most significant sequestering protein being the TTR [60].”
Ahmad, S. S., & Kamal, M. A. (2019) · Protein and Peptide Letters · doi:10.2174/0929866526666190405125334 · Cited by 6
Cerebrospinal Fluid Biomarkers for Mild Cognitive Impairment
Bryś, M., Mosconi, L., Santi, S. D., Rich, K. E., & de Leon, M. J. (2006) · Aging Health · doi:10.2217/1745509x.2.1.111 · Cited by 5
Zhang, D., Wang, Z., Wang, X., Yue, W., Zhang, L., Gao, Z., Li, M., Zhou, X., Li, Z., Huang, G., et al. (2025) · Lipids · doi:10.1002/lipd.12436 · Cited by 5
Gertz, M. A., Aras, M. A., Bart, N., Brannagan, T. H., Griffin, J. M., Kontorovich, A., & Rosen, A. M. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2536755 · Cited by 5
Uptake of Aβ by OATPs might be a new pathophysiological mechanism of Alzheimer disease
Wen, J., Zhao, M., Sun, W., Cheng, X., Yu, L., Cao, D., & Li, P. (2021) · BMC Neuroscience · doi:10.1186/s12868-021-00658-9 · Cited by 5
Gu, T., Ma, S., Liu, W., & Wang, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178310 · Cited by 3
Wang, Q., Hu, F.-R., Gou, X., Wang, S., & Ji, N. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl36597 · Cited by 6
Does amyloid b precursor protein gene expression have a role in diagnosis of biliary atresia?
Nagi, S. A. M., Abdallah, H., Elgazzar, A. A., Ayoub, B., Ali, M. S., & Sabry, M. (2023) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2023.132818 · Cited by 3
Sun, R., Zimbalski, L.-K., Schreyer, S., Baidoe‐Ansah, D., Harutyunyan, A., Heuser, A., Lippert, R. N., Spranger, J., Mai, K., & Brachs, S. (2025) · Biology of Sex Differences · doi:10.1186/s13293-025-00737-0 · Cited by 3
Ito, S., Iwata, Y., Otsuka, M., Kaneko, Y., Ogata, S., Yagi, R., Uemura, T., Masuda, T., Saito, T., Saido, T. C., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.10.051 · Cited by 2
Maltsev, A. V., & Galzitskaya, O. V. (2010) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750810030030 · Cited by 2
The microbiome shapes immunity in a sex-specific manner in mouse models of Alzheimer’s diseasePreprint
Bostick, J. W., Connerly, T. J., Thron, T., Needham, B. D., Fonseca, M. D. C., Kaddurah-Daouk, R. F., Knight, R. D., & Mazmanian, S. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.07.593011 · Cited by 2
“The liver, kidneys, spleen, and small intestine are important sites for the clearance of circulating Aβ and may act as hubs for activation of systemic immunity [53,54].”
BackgroundUnderstanding the Liver’s Role in the Clearance of Aβ40
Lockwood, G. P., Hunt, N. J., Kockx, M., Kang, S. W., Couteur, D. G. L., & Cogger, V. C. (2024) · Livers · doi:10.3390/livers4020018 · Cited by 1
Bhattacharjee, A., Purohit, P., & Roy, P. K. (2024) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2024.111890 · Cited by 1
Lyu, H., Ye, Y., Lui, V. C. H., & Wang, B. (2022) · Medical Hypotheses · doi:10.1016/j.mehy.2022.110901 · Cited by 1
Bhattacharjee, A., & Roy, P. K. (2024) · Brain Disorders · doi:10.1016/j.dscb.2023.100112 · Cited by 1
Associations of Serum Liver Function with Cerebral Blood Flow in Patients with Alzheimer’s Disease
Wang, H., Shi, L., Luo, S., Luo, Y., Xu, C., Qiu, G., Guo, Q., Chen, C., Lu, T., Liu, K., et al. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230102 · Cited by 1
“The liver was the major organ responsible for plasma clearance of A (cid:2) 40 / 42 [11–13].”
BackgroundThe Role of Apolipoprotein E Concentration and Isoform in Amyloid-beta Metabolism In Vivo
Castellano, J. M. (2011) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7416v3s
Optimization of anti-Abeta antibody therapy
Karlnoski, R. (2007) · Digital Commons - University of South Florida (University of South Florida)
Cytotoxic properties of amyloidogenic L68Q cystatin C. A search for therapeutic agents
Ingólfsdóttir, I. E. (2013)
Modulating Amyloid Beta Clearance by Altering Cellular and Whole Brain Apolipoprotein E Metabolism
Basak, J. M. (2014) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/k7dz06bk
“Aβ is actively transported across the blood-brain barrier into the blood, where it is then either catabolized by the liver or excreted through the kidney (Ghiso et al., 2004; Zlokovic, 2008).”
BackgroundInfluentialSensibilidad de biomarcadores en el líquido cefalorraquídeo en enfermedades neurodegenerativas
Ribas, G. G., Gómez, I. R., López-Sendón, J. L., Fernandez, M., Bascuñana, M., & de Yébenes, J. G. (2011) · Alzheimer Realidades e investigación en demencia · doi:10.5538/1137-1242.2011.49.26 · Cited by 1
Miller, B. (2015) · Arizona State University Library Digital Repository (Arizona State University)
KatoKazunori, M., & HoriAtsushi, H. (2012)
DIET INFLUENCES PERIPHERAL AMYLOID β METABOLISM: A ROLE FOR CIRCULATING INSULIN-LIKE GROWTH FACTOR IPreprint
Herrero-Labrador, R., Trueba-Sáiz, Á., Martinez‐Rachadell, L., de Sevilla, E. F., Díaz-Pacheco, S., Fernandez, A. F., & Aleman, I. T. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.09.180265
Maltsev, A. V., Dovidchenko, N. V., Uteshev, V. K., Sokolik, V. V., Shtang, O. M., Yakushin, M. A., Sokolova, N. M., Surin, A. K., & Galzitskaya, O. V. (2013) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750813040057 · Cited by 2
de Araújo, A. A., Leitão, R. F. D. C., Pirih, F. Q. M., & Oriá, R. B. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_21-1 · Cited by 1
Wen, J., Zhao, M., Sun, W., Cheng, X., Yu, L., Cao, D., & Li, P. (2021) · Figshare · doi:10.6084/m9.figshare.16620739
Lai, P.-H., Wang, T.-H., Zhang, N.-Y., Wu, K.-C., Yao, C.-C. J., & Lin, C.-J. (2021) · Figshare · doi:10.6084/m9.figshare.13669377
Wen, J., Zhao, M., Sun, W., Cheng, X., Yu, L., Cao, D., & Li, P. (2021) · Figshare · doi:10.6084/m9.figshare.16620700
Wen, J., Zhao, M., Sun, W., Cheng, X., Yu, L., Cao, D., & Li, P. (2021) · Figshare · doi:10.6084/m9.figshare.16620697
Nakano, M., Kondo, K., Ishiki, K., Moniruzzaman, M., Mitsuishi, Y., KADOTA, A., Watanabe, S., Yamashita, K., Miura, M., Iwanaga, S., et al. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251409337
“31 In contrast, AD biomarker concentrations in our human plasma samples were not associated with plasma ALT and γ -GTP activities, which are blood markers of hepatocyte damage and liver dysfunction.”
Systemic Amyloid-β Metabolism in Alzheimer’s Disease
Dong-yu, F., Wang, J., Gu, B. J., Masters, C. L., & Wang, Y. (2026) · Springer eBooks · doi:10.1007/978-981-95-5222-1_7
Raber, J., & Nielsen, H. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_41-1
Advances in Self‐Assembly Artificial Chaperone for Protein Folding Regulation
Zhao, S., Zong, X., Shi, L., & Huang, F. (2026) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70059
Mahmoudi, A.-E.-R. (2015) · theses.fr (ABES) · doi:10.70675/5f05520ez1713z4991za6c8z055ab117e2bb
Raajasekar, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9252110/v1
Metadata
- Authors
- Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B.
- Affiliations
- New York University (US)
- Instituto de Salud Carlos III (ES)
- Corresponding author
- Ghiso, Jorge
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 279
- Issue
- 44
- Pages
- 45897-45908
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2062647232
- Cited by
- 209
- References
- 68
- Citations by year
- 2026: 13 · 2025: 15 · 2024: 18 · 2023: 5 · 2022: 9 · 2021: 19 · 2020: 15 · 2019: 8 · 2018: 6 · 2017: 8 · 2016: 7 · 2015: 8 · 2014: 8 · 2013: 11 · 2012: 11
- FWCI
- 4.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 5832 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P01AG010491, AG10491, R01AG008721, AG-08721, AG05891)
- National Institute of Neurological Disorders and Stroke (NS 38777, R01NS038777)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- amyloid-beta, Aβ40, amyloid-beta 42, plasma clearance, hepatic uptake, biliary excretion, hepatocytes, peptide oligomerization, peptide conformation, beta-sheet, endocytosis, HepG2 cells, Alzheimer's disease
- MeSH terms
- Amino Acid Sequence, Animals, Bile, Humans, Iodine Radioisotopes, Liver, Male, Molecular Sequence Data, Tissue Distribution, Amyloid beta-Peptides, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.